ALDX Catches Eye, RVNC Faces Busy Year Ahead, SRPT Plunges On DMD Trial Data
BEIJING (dpa-AFX) - Today s Daily Dose brings you news about Alnylam s transthyretin-mediated (ATTR) amyloidosis trial results; Sarepta s mixed results of investigational gene therapy SRP-9001 in patients with Duchenne muscular dystrophy; Aldeyra s dry eye disease trial results; and Revance s anticipated milestones.
Read on.
1. Aldeyra Catches Investor s Eye
Aldeyra Therapeutics Inc. s (ALDX) run-in cohort of phase III trial of Reproxalap in patients with dry eye disease has achieved statistical significance for ocular redness, an FDA-approvable sign, and clinical symptoms of ocular dryness and discomfort.
Dry eye disease is a common inflammatory disease affecting an estimated 34 million or more adults in the United States. The disease is characterized by insufficient moisture and lubrication in the anterior surface of the eye, leading to dryness, inflammation, pain, discomfort, irritation, diminished q
Coldwater, MI, USA / WTVB | 1590 AM · 95.5 FM | The Voice of Branch County
Jan 6, 2021 7:39 AM
(Reuters) - The European Union s drug watchdog on Wednesday authorized emergency use of Moderna Inc s COVID-19 vaccine, nearly two weeks after approving Pfizer Inc and BioNTech SE s shot for the virus.
On Tuesday, Israel became the first country outside North America to grant authorization to Moderna s vaccine. The United States and Canada have already started rolling out the two-dose vaccine.
Below are more details on Moderna s vaccine:
VACCINE TECHNOLOGY
- The vaccine, called mRNA-1273, is based on messenger RNA (mRNA) technology, which relies on synthetic genes that can be generated and manufactured in weeks, and produced at scale more rapidly than conventional vaccines.